AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14760123 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 20
Study 11281054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose mutant tissue-type plasminogen activator (mt-PA), monteplase, 80 x 10(4) U bolus
Number of subjects: 164
Study 11281054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose mutant tissue-type plasminogen activator (mt-PA), monteplase
Number of subjects: 164
Study 11281054 — intervention group
Group type: COMPARATOR
Intervention: Control group (no administration of mt-PA)
Number of subjects: 164
Study 9548608 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon stopflow infusion combined with micro‐embolization
Number of subjects: 100
Study 9548608 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopflow infusion of the celiac axis combined with microspheres
Number of subjects: 100
Study 9548608 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial infusion with tumor adjusted concentrations
Number of subjects: 100
Study 9548608 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pain response
Number of subjects: 100
Study 9548608 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 100
Study 7923966 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 1,25(OH)2D3
Number of subjects: 7
Study 7923966 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) 1,25(OH)2D3
Number of subjects: 7
Study 3187415 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible fiberoptic cystourethroscopy
Number of subjects: 30
Study 3187415 — intervention group
Group type: COMPARATOR
Intervention: Conventional cystourethroscopy
Number of subjects: 30
Study 31517597 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (received free radon and air nicotine test kits, report back, telephone support, and $600 voucher for mitigation)
Number of subjects: 515
Study 31517597 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 515
Study 31517597 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (with high radon levels at baseline)
Number of subjects: 515
Study 31517597 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 515
Study 27918762 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week alternating treatment schedule of pazopanib 800 mg/d and everolimus 10 mg/d (rotating arm)
Number of subjects: 101
Study 27918762 — intervention group
Group type: COMPARATOR
Intervention: Continuous pazopanib 800 mg/d (control arm)
Number of subjects: 101
Study 25753207 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g aspirin
Number of subjects: 16
Study 25753207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 23286420 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) meal
Number of subjects: 10
Study 23286420 — intervention group
Group type: COMPARATOR
Intervention: High Glycemic Index (HGI) meal
Number of subjects: 10
Study 21713395 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy/3 fractions/15 days (arm A)
Number of subjects: 71
Study 21713395 — intervention group
Group type: COMPARATOR
Intervention: 40 Gy/4 fractions/22 days (arm B)
Number of subjects: 71
Study 19452582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine infusion at port sites
Number of subjects: 72
Study 19452582 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 72
Study 16442896 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbufiban
Number of subjects: 150
Study 16442896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 15250181 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study 15250181 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 11167672 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal drops (800 microg doses)
Number of subjects: 0
Study 11167672 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray (800 microg doses)
Number of subjects: 0
Study 9051855 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum substance P levels in rheumatoid arthritis patients
Number of subjects: 0
Study 9051855 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 8385022 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (13C labelled) at doses between 12.5 and 100 mg
Number of subjects: 10
Study 8385022 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (13C labelled)
Number of subjects: 10
Study 3708186 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram (0.5 mg X kg‐1 lean body mass bolus followed by 1 mg X min‐1 infusion)
Number of subjects: 4
Study 3708186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 31239638 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg in 20 mL of normal saline
Number of subjects: 100
Study 31239638 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg
Number of subjects: 100
Study 31239638 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 100
Study 29730208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartilage fragments
Number of subjects: 116
Study 29730208 — intervention group
Group type: COMPARATOR
Intervention: Control (no cartilage fragments)
Number of subjects: 116
Study 25355940 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 1866
Study 25355940 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 1866
Study 24424627 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided radiotherapy (IGRT)
Number of subjects: 30
Study 24424627 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (RT) - Group 1 (single photon field, posterior-anterior direction)
Number of subjects: 30
Study 24424627 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (RT) - Group 2 (single photon field, posterior-anterior direction)
Number of subjects: 30
Study 24424627 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (RT) - Group 3 (three-dimensional conformal treatment plan)
Number of subjects: 30
Study 22244035 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming training
Number of subjects: 43
Study 22244035 — intervention group
Group type: COMPARATOR
Intervention: Attention time controls
Number of subjects: 43
Study 19535697 — intervention group
Group type: EXPERIMENTAL
Intervention: Licorice gargle (0.5 g licorice in water)
Number of subjects: 40
Study 19535697 — intervention group
Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 40
Study 17211432 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated donor (DV+ group)
Number of subjects: 111
Study 17211432 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated donor (DV- group)
Number of subjects: 111
Study 17211432 — intervention group
Group type: EXPERIMENTAL
Intervention: High antibody concentration donors
Number of subjects: 111
Study 17211432 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-specific antibody concentration donors
Number of subjects: 111
Study 16420082 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/day)
Number of subjects: 526
Study 12002756 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim-mobilised PBPCs (n = 37)
Number of subjects: 72
Study 12002756 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow transplant (ABMT) (n = 35)
Number of subjects: 72
Study 12002756 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 72
Study 12002756 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 72
Study 10098104 — intervention group
Group type: EXPERIMENTAL
Intervention: Constrained Longitudinal Splines (CLS) semiparametric method
Number of subjects: 90
Study 10098104 — intervention group
Group type: COMPARATOR
Intervention: Standard nonlinear weighted least squares approach (reference value)
Number of subjects: 90
Study 10098104 — intervention group
Group type: EXPERIMENTAL
Intervention: NONMEM POSTHOC method using parametric and CLS methods
Number of subjects: 90
Study 10098104 — intervention group
Group type: EXPERIMENTAL
Intervention: Monte Carlo simulation approach
Number of subjects: 90
Study 7618480 — intervention group
Group type: EXPERIMENTAL
Intervention: Static handgrip exercise at 30% of maximal voluntary contraction
Number of subjects: 8
Study 7618480 — intervention group
Group type: EXPERIMENTAL
Intervention: One-leg knee extension exercise at 30% of maximal voluntary contraction
Number of subjects: 8
Study 1514339 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg/kg
Number of subjects: 76
Study 1514339 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 4 mg/kg
Number of subjects: 76
Study 6391136 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 1436
Study 6391136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1436
Study 31061074 — intervention group
Group type: EXPERIMENTAL
Intervention: Health TAPESTRY
Number of subjects: 312
Study 31061074 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 312
Study 29386413 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D therapy, 50000 IU intramuscularly (IM) monthly for 6 months
Number of subjects: 85
Study 29386413 — intervention group
Group type: COMPARATOR
Intervention: Distilled water IM (control group)
Number of subjects: 85
Study 27941696 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmentally-friendly (EF) wallpaper
Number of subjects: 31
Study 27941696 — intervention group
Group type: COMPARATOR
Intervention: Polyvinyl chloride (PVC) wallpaper
Number of subjects: 31
Study 24906244 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV and AIDSVAX B/E prime-boost regimen (vaccine)
Number of subjects: 400
Study 24906244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 22812438 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Maxillary Expansion (SME)
Number of subjects: 26
Study 22812438 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion (RME)
Number of subjects: 26
Study 20693796 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-ethanol
Number of subjects: 0
Study 20693796 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine
Number of subjects: 0
Study 17918152 — intervention group
Group type: COMPARATOR
Intervention: Former smokers
Number of subjects: 103081
Study 17918152 — intervention group
Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 103081
Study 17918152 — intervention group
Group type: COMPARATOR
Intervention: Women who smoked for more than 20 years
Number of subjects: 103081
Study 17918152 — intervention group
Group type: COMPARATOR
Intervention: Smoking intensity (pack-years) and duration (number of years)
Number of subjects: 103081
Study 15733266 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling
Number of subjects: 577
Study 15733266 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling
Number of subjects: 577
Study 15733266 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 577
Study 15733266 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 577
Study 12877416 — intervention group
Group type: COMPARATOR
Intervention: 10% carbamide peroxide for two weeks (Group A - negative control)
Number of subjects: 60
Study 12877416 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium perborate mixed with 3% hydrogen peroxide (modified walking bleach technique) for four weeks (Group B)
Number of subjects: 60
Study 12877416 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide for two weeks (Group C)
Number of subjects: 60
Study 10516692 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (5 microg/kg/day) starting on day 0
Number of subjects: 69
Study 10516692 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (5 microg/kg/day) starting on day +5
Number of subjects: 69
Study 10516692 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (5 microg/kg/day) starting on day +10
Number of subjects: 69
Study 10516692 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim starting on day +10
Number of subjects: 69
Study 10516692 — intervention group
Group type: COMPARATOR
Intervention: All groups (day 0, day +5, day +10)
Number of subjects: 69
Study 7516191 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (two daily subcutaneous injections of 54 or 108 micrograms)
Number of subjects: 3
Study 7516191 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 3
Study 2684990 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad arm sling
Number of subjects: 60
Study 2684990 — intervention group
Group type: COMPARATOR
Intervention: Reduction and fixation with a coracoclavicular screw
Number of subjects: 60
Study 794520 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 210
Study 794520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin
Number of subjects: 210
Study 794520 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibacterial agent)
Number of subjects: 210
Study 31640647 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of district mental health care plan (MHCP)
Number of subjects: 1983
Study 28615271 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised moderate-to-high intensity aerobic exercise (1 hour, 3 times weekly for 16 weeks)
Number of subjects: 200
Study 28615271 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 200
Study 28615271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 200
Study 26194272 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII + sitagliptin
Number of subjects: 217
Study 26194272 — intervention group
Group type: COMPARATOR
Intervention: CSII
Number of subjects: 217
Study 23916805 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass graft surgery
Number of subjects: 2203
Study 23916805 — intervention group
Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass graft surgery
Number of subjects: 2203
Study 23916805 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump to on-pump conversions
Number of subjects: 2203
Study 23916805 — intervention group
Group type: COMPARATOR
Intervention: On-pump and off-pump comparison
Number of subjects: 2203
Study 21438987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ural (sodium bicarbonate)
Number of subjects: 300
Study 21438987 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 300
Study 18313122 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary Symptom Profile (USP) questionnaire
Number of subjects: 328
Study 16710711 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (300 mg/day) plus vitamin C (500 mg/day) for 12 weeks
Number of subjects: 17
Study 16710711 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exposed staff)
Number of subjects: 17
Study 16710711 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical anaesthesiology staff before antioxidant treatment
Number of subjects: 17
Study 12566215 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face counselling
Number of subjects: 205
Study 12566215 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counselling
Number of subjects: 205
Study 12566215 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 205
Study 11055032 — intervention group
Group type: EXPERIMENTAL
Intervention: Preschool education (intervention)
Number of subjects: 0
Study 11055032 — intervention group
Group type: EXPERIMENTAL
Intervention: Random allocation (intervention)
Number of subjects: 0
Study 8836715 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal piezoelectric lithotripsy (ESWL, n = 79)
Number of subjects: 125
Study 8836715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal electrohydraulic lithotripsy (EHL, n = 46)
Number of subjects: 125
Study 8836715 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment including ESWL, EHL, and intracorporeal laser lithotripsy
Number of subjects: 125
Study 8836715 — intervention group
Group type: COMPARATOR
Intervention: Both groups (ESWL and EHL)
Number of subjects: 125
Study 8268363 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg, orally, twice daily for 3 days)
Number of subjects: 106
Study 8268363 — intervention group
Group type: COMPARATOR
Intervention: Placebo (orally, twice daily for 3 days)
Number of subjects: 106
Study 3519327 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback, relaxation-response training, and pain behavior management
Number of subjects: 18
Study 3519327 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation-response training and pain behavior management
Number of subjects: 18
Study 3519327 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 18
Study 29902597 — intervention group
Group type: EXPERIMENTAL
Intervention: Translaminar approach (key-hole laminotomy)
Number of subjects: 48
Study 29902597 — intervention group
Group type: COMPARATOR
Intervention: Interlaminar approach
Number of subjects: 48
Study 27564310 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable scaffold (Absorb)
Number of subjects: 501
Study 27564310 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting metallic stent (XIENCE)
Number of subjects: 501
Study 24472112 — intervention group
Group type: EXPERIMENTAL
Intervention: PA/MD model (physician assistants functioning as hospitalists alongside medical doctors)
Number of subjects: 460
Study 24472112 — intervention group
Group type: COMPARATOR
Intervention: MD model (traditional model with medical doctors as hospitalists)
Number of subjects: 460
Study 24472112 — intervention group
Group type: EXPERIMENTAL
Intervention: PA/MD model
Number of subjects: 460
Study 22420584 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral methadone (MG)
Number of subjects: 68
Study 22420584 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 68
Study 20434108 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 63
Study 20434108 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 63
Study 20434108 — intervention group
Group type: EXPERIMENTAL
Intervention: Both laryngoscopes
Number of subjects: 63
Study 18382267 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0
Study 18382267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15756571 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 1%
Number of subjects: 45
Study 15756571 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimexolone 1%
Number of subjects: 45
Study 15756571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.5%
Number of subjects: 45
Study 15756571 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 45
Study 12004637 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart reminder intervention
Number of subjects: 0
Study 12004637 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chart reminder)
Number of subjects: 0
Study 10738351 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 392
Study 10738351 — intervention group
Group type: COMPARATOR
Intervention: PTCA (Percutaneous Transluminal Coronary Angioplasty)
Number of subjects: 392
Study 10738351 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 392
Study 10738351 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and PTCA
Number of subjects: 392
Study 7806038 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa (10 MU/m2 three times weekly for 12 weeks)
Number of subjects: 50
Study 1941387 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (200 units/kg every other day for 10 doses)
Number of subjects: 19
Study 1941387 — intervention group
Group type: COMPARATOR
Intervention: Erythrocyte transfusion
Number of subjects: 19
Study 1941387 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 19
Study 7079889 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure continuous-flow water irrigation system
Number of subjects: 14
Study 7079889 — intervention group
Group type: COMPARATOR
Intervention: Routine method of intermittent bladder emptying
Number of subjects: 14
Study 7079889 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple suprapubic shunt
Number of subjects: 14
Study 30856124 — intervention group
Group type: EXPERIMENTAL
Intervention: Soymilk (SMS; n = 11)
Number of subjects: 22
Study 30856124 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA; n = 11)
Number of subjects: 22
Study 30573783 — intervention group
Group type: EXPERIMENTAL
Intervention: Real RF exposure (UMTS)
Number of subjects: 60
Study 30573783 — intervention group
Group type: EXPERIMENTAL
Intervention: Real RF exposure (LTE)
Number of subjects: 60
Study 30573783 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 60
Study 26724252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative group
Number of subjects: 3
Study 26724252 — intervention group
Group type: COMPARATOR
Intervention: Individual group
Number of subjects: 3
Study 24753225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-emotional training paradigm (emotional faces memory task, EFMT) involving eight sessions over 4 weeks
Number of subjects: 21
Study 24753225 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (control training, CT)
Number of subjects: 21
Study 21410633 — intervention group
Group type: EXPERIMENTAL
Intervention: da Vinci S robot
Number of subjects: 100
Study 21410633 — intervention group
Group type: COMPARATOR
Intervention: Standard da Vinci robot
Number of subjects: 100
Study 19670810 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg twice a day for 3 days)
Number of subjects: 108
Study 19670810 — intervention group
Group type: COMPARATOR
Intervention: Phosphomycin (a single 3.0 g dose)
Number of subjects: 108